Last reviewed · How we verify

Xuezhikang capsule — Competitive Intelligence Brief

Xuezhikang capsule (Xuezhikang capsule) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal lipid-lowering agent; statin-containing traditional Chinese medicine. Area: Cardiovascular.

marketed Herbal lipid-lowering agent; statin-containing traditional Chinese medicine Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Xuezhikang capsule (Xuezhikang capsule) — China Academy of Chinese Medical Sciences. Xuezhikang reduces blood lipids and improves blood circulation by inhibiting cholesterol synthesis and modulating lipid metabolism through its active compounds derived from red yeast rice.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xuezhikang capsule TARGET Xuezhikang capsule China Academy of Chinese Medical Sciences marketed Herbal lipid-lowering agent; statin-containing traditional Chinese medicine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal lipid-lowering agent; statin-containing traditional Chinese medicine class)

  1. China Academy of Chinese Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xuezhikang capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/xuezhikang-capsule. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: